OssDsign has signed an agreement with an Integrated Delivery Network (IDN) in the western US, which represents the company's largest sales opportunity in the region. The agreement gives IDN-affiliated hospitals access to OssDsign Catalyst at special prices. The company has focused on the eastern US since 2021 but is now expanding westward. The agreement is based on strong clinical data from the PROPEL study showing an 88,4 percent fusion rate.
|
Published December 5, 2025
OssDsign signs agreement in the western US
Text:
News Desk [email protected]
Notes
GSK acquires RAPT Therapeutics in billion-dollar deal
Brain+ files for reorganization
Affibody raises SEK 307 million for investment in radioligand therapy
AstraZeneca directly lists common shares on NYSE
AAX Biotech and Vascurie begin collaboration on cardiovascular diseases
Immunovia begins launch in California after approval
Ortoma reports preliminary figures and new financial targets
NEWSLETTER
Today's news roundup
News roundup Tuesday, January 20
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Global Forum 2026
This May, our premier event returns, dramatically expanded yet carefully curated to ensure a welcoming and high-value experience. We ha...
Investing in Life Science
Set in vibrant Stockholm, the Swedish finance capital, this boutique investor event connects regional life science leaders looking for strategic...
Recommended
Sprint Bioscience at J.P. Morgan Healthcare Week
The hunt for Nordic gems begins – LSI mobilizes 35 angels in new expansion
BioStock enters new chapter – Hanna Norrlid appointed CEO
J&J tops the list – here are the 5 biggest biopharma deals of 2025
Global data sees renewed optimism after tough year
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account